Do you need a Fernisone lawyer in Washington, DC? Contact one of our Fernisone lawyers in Washington, DC now.
Home : FDA Drug Database : Fernisone : News Articles
Fernisone - News Articles
-
Jun 23, 2008
DG News -
The current approval was based on the VISTA1 (Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) trial -- an tle cell lymphoma who have received at least one prior therapy. SOURCE: Millennium ... -
Jun 24, 2008
RTT News, NY -
(RTTNews) - GPC Biotech AG (GPCB: News, Chart, Quote ) said Tuesday that it has initiated a Phase 2 study to evaluate its investigational drug satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer or HRPC, who have undergone previous ... -
Jun 24, 2008
RTT News, NY -
(RTTNews) - GPC Biotech AG (GPCB: News, Chart, Quote ) said Tuesday that it has initiated a mid-stage trial to assess satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer or HRPC, and previously treated with doxetaxal or Taxotere. The ... -
Jun 25, 2008
MedPage Today, NJ -
Patients were randomized to receive nine six-week cycles of oral melphalan plus prednisone or melphalan plus bortezomib. Patients received melphalan (9 mg/m 2 ) plus prednisone (60 mg/m 2 ) daily for four days every six weeks. The same melphalan schedule ... -
Jun 27, 2008
Cape Breton Post, Canada -
At the vet’s recommendation, they started Harley on a course of steroids (prednisone) to reduce any inflammation that often accompanies cancer and to stimulate his appetite, perhaps giving the trio just a bit more time together. Weeks, however, turned to months, ... -
Jun 23, 2008
Pharmaceutical Business Review -
By Staff Writer The company's co-development partner, Johnson & Johnson Pharmaceutical R&D, also has filed a corresponding application with the European Medicines Evaluation Agency. The current approval was based on an international, multicenter, open-label, active-control trial in previously ... -
Jun 23, 2008
Trading Markets (press release), CA -
NORTH HOLLYWOOD, Calif., Jun 23, 2008 (BUSINESS WIRE) -- MLNM | Quote | Chart | News | PowerRating -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded ... -
Jun 23, 2008
Trading Markets (press release), CA -
Jun 23, 2008 (Datamonitor via COMTEX) -- MLNM | Quote | Chart | News | PowerRating -- Millennium Pharmaceuticals, the Takeda oncology company, and Takeda Pharmaceutical Company, have announced that the FDA has approved Velcade for patients with previously untreated multiple myeloma. ... -
Jun 23, 2008
Cancer Consultants, ID -
The United States Food and Drug Administration (FDA) has approved Velcade® (bortezomib) as initial therapy for the treatment of multiple myeloma. Velcade is already approved for the treatment of patients with multiple myeloma who have received prior therapies, as well ... -
Jun 23, 2008
Prescribing Reference, New York -
The FDA has approved Velcade (bortezomib injection, from Millennium) for patients with previously untreated multiple myeloma. This approval is based on results from the VISTA trial which showed a 30% complete remission rate with Velcade in combination with ...
-
Jun 23, 2008
Cancer Consultants, ID -
Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited have received an additional approval by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment ... -
Jun 23, 2008
TMCnet -
(BioWorld Today Via Acquire Media NewsEdge) Cambridge, Mass.-based Millennium Pharmaceuticals Inc., now a subsidiary of Japanese firm Takeda Pharmaceuticals Inc., won U.S. marketing approval Friday to expand the labeling of Velcade (bortezomib) as a first-line treatment in patients ... -
Jun 23, 2008
TheStreet.com -
Japanese pharmaceutical company Takeda said late Friday that the Food and Drug Administration approved Velcade for patients with previously untreated multiple myeloma. The approval was expected, although some on Wall Street were surprised by the broadness of the label ... -
Oct 8, 2007
Wilkes Barre Times-Leader, PA -
I’m taking prednisone, but my doctor said that I waited four weeks too long to get treatment with the medication Valtrex. He said that would have really helped out. What do you suggest I do for the pain? A: Shingles is a ... -
Sep 20, 2007
Trading Markets, CA -
The combination of Velcade with melphalan and prednisone surpassed all efficacy endpoints, including time-to-disease progression, complete remission rate, progression-free survival and overall survival, and did so, much earlier than expected. We are excited at the possibility this ... -
Sep 18, 2007
RTT News, NY -
The company said interim results of the trial of VELCADE in combination with melphalan and prednisone demonstrated a highly statistically significant improvement in all efficacy measures. The combined stream enhancement in time-to-disease progression, complete remission rate, progression-free survival and overall ... -
Sep 18, 2007
Reuters -
stopped early to allow patients still being treated with the other cancer treatments, melphalan and prednisone, to have Velcade added to their therapy. Millennium is co-developing Velcade with a unit of Johnson& Johnson (JNJ.N: ... -
Sep 24, 2007
Canada NewsWire (press release), Canada -
Following the positive results of a European Phase III trial (CAPRA-1; Circadian Administration of Prednisone in Rheumatoid Arthritis), Nitec submitted a ... -
Oct 5, 2007
Medical News Today, UK -
If an elderly multiple myeloma patient receives thalidomide on top of his/her chemotherapy treatment of melphalan plus prednisone his/her survival improves substantially, according to an article in The Lancet , this week's edition. For over four decades ... -
Oct 4, 2007
Ivanhoe, FL -
Patients received either the standard treatment of prednisone and melphalan alone, prednisone, melphalan and thalidomide or reduced-intensity stem cell transplantation using melphalan. After about 51 months, the median overall survival rates were 33.2 months for the ...
Do you need a Fernisone lawyer in Washington, DC? Contact one of our Fernisone lawyers in Washington, DC now.
